Clinical 13:05 ET · Sep 2, 2026 ● Checked against the source HRMY Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026. Andre·1 min read ID: HRMY-2026-09-02-1305 TickersHRMY Clinical DeskClinical PublishedSep 2, 2026 · 13:05 ET AccessPro story MORE FROM THE DESK Sep 11 · 08:33 ETIMMUTEP Narrows Efti Strategy After TACTI-004 Failure, Blames ManufacturingSep 10 · 10:04 ETIMUNON Signs CRADA With National Cancer Institute for IMNN-001Sep 10 · 08:45 ETEYEPOINT Details LUGANO Miss, Says Nine Patients Drove Failed EndpointSep 9 · 06:13 ETBRIDGEBIO Says Oral Infigratinib Cut Ear Infections, Stabilized Sleep Apnea
